IBD
Clinical trials for IBD explained in plain language.
Never miss a new study
Get alerted when new IBD trials appear
Sign up with your email to follow new studies for IBD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New biologic drug brazikumab tested for Crohn's – trial cut short
Disease control TerminatedThis study tested brazikumab, an experimental biologic drug, in 89 adults with moderate-to-severe Crohn's disease. Participants received either brazikumab, a placebo, or an active comparator (Humira) to see if the drug could improve symptoms and heal the gut lining. The trial was…
Matched conditions: IBD
Phase: PHASE2, PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug brazikumab aims to tame ulcerative colitis Flare-Ups
Disease control TerminatedThis phase 2 trial tested brazikumab in 242 adults with moderate-to-severe ulcerative colitis. Participants received either brazikumab or a placebo intravenously and then as injections over 54 weeks. The goal was to see if the drug could improve symptoms and heal the colon lining…
Matched conditions: IBD
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Crohn's drug trial halted early: what happened?
Disease control TerminatedThis study was designed to see if brazikumab is safe and tolerable over the long term for people with moderate to severe Crohn's disease. It enrolled 18 participants who had previously been in a related study. The trial was terminated early, meaning it did not reach its planned e…
Matched conditions: IBD
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC